港股異動 | 中國抗體-B(3681.HK)高開3.59% SN1011新藥研究申請獲CDE受理
格隆匯6月30日丨中國抗體-B(3681.HK)高開3.59%,報4.33港元,暫成交47.9萬港元,最新總市值43.6億港元。中國抗體昨日晚間宣佈,於6月22日,一項SN1011的新藥研究申請("新藥研究申請",針對自身免疫性疾病)已提交予中國國家藥品監督管理局藥品審評中心,並於6月25日獲受理。公司計劃於當前新藥研究申請獲批後,立即在中國開始I期臨牀試驗,並後續開展和系統性紅斑狼瘡及類風濕關節炎適應症相關的臨牀研發項目。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.